Lisa Miller


Persistence Paved the Path of Discovery for an Immunotherapy Pioneer

October 8th 2018

Thomas F. Gajewski, MD, PhD, has made inroads in the field of cancer immunotherapy, most notably discovering the connections between the microbiome and clinical outcomes—findings that will enable the creation of microbiota-modulating interventions to improve outcomes in patients undergoing cancer treatments.

Debating the True Benefit of Adjuvant TKIs in High-Risk RCC

October 4th 2017

Adjuvant therapy with tyrosine kinase inhibitors for patients with high-risk renal cell carcinoma (RCC) who have undergone a nephrectomy may be supported by level IIa evidence from the National Comprehensive Cancer Network guidelines.

Proposed Changes to 340B May Curb Hospital Abuses

September 2nd 2017

Outpatient branded drug sales in the 340B Drug Pricing Program now amount to almost 8% of the total market, well up from 5.4% in 2012.

Identifying Actionable Biomarkers Crucial to Advancing Precision Medicine in MBC

July 28th 2017

While several biomarkers have been identified in patients with breast cancer, including ESR1 and PIK3CA mutations, not all of these are driver mutations that can be effectively targeted with treatment.

Trastuzumab Combos, Novel Agents Key to Advancing HER2+ Breast Cancer Care

July 28th 2017

Experts are trying to determine whether combination regimens with additional HER2-directed therapies or alternative therapies could improve responses in HER2-positive breast cancer without added toxicities.

Changes Planned for MPN Guidelines

May 26th 2017

The National Comprehensive Cancer Network published its first set of guidelines for myeloproliferative neoplasms in October 2016 and is already looking to update and expand these guidelines.

Expert Discusses Impact, Importance of Genetic Testing in Cancer

April 28th 2017

Howard A. “Skip” Burris III, MD, detailed the benefits of performing next-generation sequencing tests on patients with cancer at the 2017 Community Oncology Conference.

Immunotherapy Agents, Combinations to Compete for Frontline NSCLC

April 17th 2017

Sukhmani Padda, MD discusses the status of ongoing clinical trials participating in this race to the frontline setting in lung cancer.

Function of IDH Mutations Can Be Exploited by PARP Inhibitors Instead of IDH Inhibitors

April 4th 2017

A phase II basket trial has been announced to test that mutations in isocitrate dehydrogenase 1 and 2 are not driver mutations that should be targeted with direct IDH inhibitors, but instead they create vulnerabilities that can be exploited through treatment with PARP inhibitors.

Antibiotic Use May Damper the Efficacy of Checkpoint Inhibitors

February 14th 2017

Use of antibiotics up to a month before treatment with a checkpoint inhibitor may decrease the efficacy of the immunotherapy agent, results of a retrospective analysis show.

Prevalence of Ph-like ALL in Adults Emphasizes Need for Targeted Clinical Trials

February 12th 2017

A recent study published in the Journal of Clinical Oncology has found that Philadelphia chromosome-like acute lymphoblastic leukemia (ALL) accounts for over 20% of all adult patients with ALL and is correlated with poor outcomes.

Pembrolizumab Demonstrates Durable Responses in Rare Subtype of Melanoma

January 31st 2017

Pembrolizumab provided durable activity for previously treated patients with mucosal melanoma, according to data coming out of 3 clinical trials.

Onartuzumab Shows No Additional Benefit When Combined With Bevacizumab in GBM

December 23rd 2016

The addition of onartuzumab to bevacizumab did not provide any increased clinical benefit in the treatment of patients with recurrent glioblastoma multiforme.

Women With Menopausal Symptoms Less Likely to Adhere to Breast Cancer Prevention Treatment

December 10th 2016

Women who are experiencing symptoms of menopause are less likely to adhere to treatment, according to findings presented at the 2016 San Antonio Breast Cancer Symposium.

Lancet Data Highlight OS Benefit for Regorafenib in HCC

December 9th 2016

Regorafenib (Stivarga) has demonstrated the first survival benefit for a systemic therapy in the second-line setting for patients with advanced hepatocellular carcinoma (HCC) who have progressed on sorafenib (Nexavar), according to results from the phase III RESORCE trial published in The Lancet.1

No Clinical Benefit With Adjuvant Ibandronate in Postmenopausal Breast Cancer

December 9th 2016

Adjuvant ibandronate (Boniva) added to hormone therapy did not provide a clinical benefit to postmenopausal patients with HR-positive, early-stage breast cancer, according to findings from the phase III TEAM IIB trial.

Everolimus Added to Fulvestrant Doubles PFS in HR+ Breast Cancer

December 7th 2016

The addition of everolimus (Afinitor) to fulvestrant (Faslodex) significantly improved progression-free survival rates in postmenopausal patients with metastatic hormone receptor–positive, HER2-negative breast cancer who are resistant to aromatase inhibitor therapy.

New Guidelines Establish Recommendations for HER2 Testing for GEA

November 21st 2016

An expert panel has issued a set of guidelines for patients with gastroesophageal adenocarcinoma, recommending that they be tested for HER2 status before initiation of targeted therapy.

Dual Biomarker Signature Holds Predictive Promise for Response to Anti-PD-L1 Therapy in NSCLC

November 16th 2016

Recent research suggests that the presence of PD-L1–positive and CD8+ cells may be useful for predicting responses in patients with non-small cell lung cancer who have been treated with durvalumab.

Expert Emphasizes Lack of Treatment Options for Medullary Thyroid Cancer

October 20th 2016

Though some patients with medullary thyroid cancer can live with their disease without progression for long periods of time, the majority will eventually enter a phase in which their cancer becomes much more aggressive.